Radius Heal (RDUS)

20.10
+0.70(+3.61%)
After Hours
19.76
-0.34(-1.69%)
- Real-time Data
  • Volume:
    1,665,266
  • Bid/Ask:
    19.72/20.21
  • Day's Range:
    19.23 - 20.34

RDUS Overview

Prev. Close
19.4
Day's Range
19.23-20.34
Revenue
248.67M
Open
19.69
52 wk Range
11.95-26.16
EPS
-1.28
Volume
1,665,266
Market Cap
916.96M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,317,655
P/E Ratio
-
Beta
1.1
1-Year Change
48.23%
Shares Outstanding
47,266,146
Next Earnings Date
Feb 24, 2022
What is your sentiment on Radius Heal?
or
Market is currently closed. Voting is open during market hours.

Radius Heal News

Radius Heal Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyBuy
Technical IndicatorsBuyNeutralStrong BuyStrong BuyNeutral
SummaryStrong BuyBuyStrong BuyStrong BuyNeutral

Radius Heal Company Profile

Radius Heal Company Profile

Employees
310

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Read More
  • RDUS (P) 0 17.99
    0
    • Good News!!!
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.